Clinical Trial Update: Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL [Phase 2]

View source ↗

Summary

Phase II multicenter trial by Fondazione Italiana Linfomi evaluating frontline rituximab plus bendamustine in frail elderly patients over 70 with diffuse large …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN